Patents by Inventor Iok-hou Pang

Iok-hou Pang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180094029
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Application
    Filed: October 18, 2017
    Publication date: April 5, 2018
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • Patent number: 9822147
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: November 21, 2017
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • Publication number: 20170165200
    Abstract: Described herein are nanoparticles comprising a mixture of a steroid, a phospholipid composition, an ?-tocopheryl compound, and a therapeutic agent wherein the ?-tocopheryl compound is presented on the surface of the nanoparticle. In some embodiments, the nanoparticles are useful for delivering a peptide or a protein. In some embodiments, the nanoparticles are formulated for ocular administration. In other embodiments, the nanoparticles are formulated to cross the blood brain barrier for the delivery of the therapeutic agents to the brain.
    Type: Application
    Filed: November 18, 2016
    Publication date: June 15, 2017
    Applicant: University of North Texas Health Science Center
    Inventors: Xiaowei DONG, Iok-Hou PANG
  • Publication number: 20170101440
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Application
    Filed: November 12, 2015
    Publication date: April 13, 2017
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • Patent number: 9187525
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: November 17, 2015
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • Publication number: 20130345136
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Application
    Filed: August 28, 2013
    Publication date: December 26, 2013
    Applicant: Alcon Research, Ltd.
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • Patent number: 8551938
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: October 8, 2013
    Assignee: Alcon Research, Ltd.
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • Publication number: 20120283260
    Abstract: The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.
    Type: Application
    Filed: July 24, 2012
    Publication date: November 8, 2012
    Applicants: ASTELLAS PHARMA INC., ALCON RESEARCH, LTD.
    Inventors: Keith D. Combrink, Suchismita Mohapatra, Mark R. Hellberg, Najam A. Sharif, Ganesh Prasanna, Iok-Hou Pang, Bryon Severns, Hwang-Hsing Chen, Abdelmoula Namil
  • Patent number: 8252793
    Abstract: The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: August 28, 2012
    Assignees: Alcon Research, Ltd., Astellas Pharma Inc.
    Inventors: Keith D. Combrink, Suchismita Mohapatra, Mark R. Hellberg, Najam A. Sharif, Ganesh Prasanna, Iok-Hou Pang, Bryon Severns, Hwang-Hsing Chen, Abdelmoula Namil
  • Publication number: 20120115870
    Abstract: An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.
    Type: Application
    Filed: January 11, 2012
    Publication date: May 10, 2012
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Debra L. Fleenor, Iok-Hou Pang, Allan R. Shepard, Mark R. Hellberg, Peter G. Klimko, Abbot F. Clark
  • Publication number: 20120046285
    Abstract: The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.
    Type: Application
    Filed: August 17, 2011
    Publication date: February 23, 2012
    Applicants: ASTELLAS PHARMA INC., ALCON RESEARCH, LTD.
    Inventors: Keith D. Combrink, Suchismita Mohapatra, Mark R. Hellberg, Najam A. Sharif, Ganesh Prasanna, Iok-Hou Pang, Bryon Severns, Hwang-Hsing Chen, Abdelmoula Namil
  • Publication number: 20120004274
    Abstract: Compositions and methods for lowering IOP and/or providing neuroprotection are disclosed. The compositions and methods are particularly directed to the use inhibitors of Jun N-terminal kinases (JNK) to lower IOP and/or provide neuroprotection.
    Type: Application
    Filed: September 14, 2011
    Publication date: January 5, 2012
    Inventors: Debra L. Fleenor, Iok-Hou Pang
  • Publication number: 20110160210
    Abstract: An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.
    Type: Application
    Filed: March 8, 2011
    Publication date: June 30, 2011
    Applicant: ALCON, INC.
    Inventors: Debra L. Fleenor, Iok-Hou Pang, Allan R. Shapard, Mark R. Hellberg, Abbot F. Clark, Peter G. Klimko
  • Publication number: 20110144127
    Abstract: Agents that stimulate nuclear translocation of Nrf2 protein and the subsequent increases in gene products that detoxify and eliminate cytotoxic metabolites are provided in a method for treating glaucomatous retinopathy or optic neuropathy. The structurally diverse agents that act on the Nrf2/ARE pathway induce the expression of enzymes and proteins that possess chemically versatile cytoprotective properties and are a defense against toxic metabolites and xenobiotics. Agents include certain electrophiles and oxidants such as a Michael Addition acceptor, diphenol, thiocarbamate, quinone, 1,2-dithiole-3-thione, butylated hydroxyanisole, flavonoid, an isothiocyanate, 3,5-di-tert-butyl-4-hydroxytoluene, ethoxyquin, a coumarin, combinations thereof, or a pharmacologically active derivative or analog thereof.
    Type: Application
    Filed: February 22, 2011
    Publication date: June 16, 2011
    Applicant: ALCON INC.
    Inventors: Robert A. Landers, Iok-Hou Pang
  • Publication number: 20110112038
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Application
    Filed: September 23, 2010
    Publication date: May 12, 2011
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • Publication number: 20110105574
    Abstract: The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 expression or PAI-1 activity. Another embodiment of the present invention is a method of treating a PAI-1-associated ocular disorder in a subject in need, comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 activity or expression.
    Type: Application
    Filed: January 14, 2011
    Publication date: May 5, 2011
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Debra L. Fleenor, Allan R. Shepard, Iok-Hou Pang, Mark R. Hellberg, Abbot F. Clark
  • Publication number: 20110098314
    Abstract: The use of HMG-CoA reductase inhibitors (e.g., statins) to treat glaucoma, control intraocular pressure, preserve the trabecular meshwork, protect against ocular neurodegeneration and/or protect against glaucomatous retinopathy is described. The preferred HMG-CoA reductase inhibitors, which are statins having an RI value of 0.2 to 0.7 (e.g., pravastatin), are administered via topical application to the affected eye(s) of the patient.
    Type: Application
    Filed: November 8, 2010
    Publication date: April 28, 2011
    Applicant: ALCON, INC.
    Inventors: Mark R. Hellberg, Debra L. Fleenor, Allan R. Shepard, Iok-Hou Pang
  • Publication number: 20110092523
    Abstract: The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).
    Type: Application
    Filed: December 16, 2010
    Publication date: April 21, 2011
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Debra L. Fleenor, Allan Shepard, Nasreen Jacobson, Iok-Hou Pang, Abbot F. Clark
  • Publication number: 20110028534
    Abstract: RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention.
    Type: Application
    Filed: October 8, 2010
    Publication date: February 3, 2011
    Applicant: ALCON, INC.
    Inventors: Allan R. Shepard, Iok-Hou Pang
  • Publication number: 20100311716
    Abstract: Compositions and methods for lowering IOP and/or providing neuroprotection are disclosed. The compositions and methods are particularly directed to the use inhibitors of Jun N-terminal kinases (JNK) to lower IOP and/or provide neuroprotection.
    Type: Application
    Filed: August 18, 2010
    Publication date: December 9, 2010
    Applicant: ALCON, INC.
    Inventors: Debra L. Fleenor, Iok-Hou Pang